ENA Respiratory

Nasal spray to boost natural antiviral defenses and prevent illness in high-risk groups

Respiratory viral infections (RVIs) – including influenza, RSV, SARSCoV-2, parainfluenza, endemic coronaviruses, and rhinovirus – remain a major source of global morbidity and mortality, driving millions of illnesses, hospitalisations, and deaths each year across the US, Australia, and other developed healthcare systems.

Infections are often mild in healthy adults, but outcomes are substantially more severe in people with chronic disease, where they frequently trigger acute exacerbations, emergency presentations, hospitalisation, functional decline, and increased mortality. Adults with chronic respiratory disease (asthma, COPD, chronic bronchitis), cardiometabolic disorders (diabetes, congestive heart failure), chronic kidney disease (CKD), immuno-compromising conditions, or chronic corticosteroid exposure are particularly vulnerable.

ENA Respiratory is developing Nasal Defence Enhancer (INNA-051) to address this gap as a convenient, once-a-week nasal spray that boosts natural antiviral defenses to prevent illness in high-risk groups, including those with chronic lung disease, older adults, and cardiometabolic conditions.

Biointelect Venturer funding for this project supports a first-in-patient Phase Ib study of INNA-051 in adults with mild asthma, validating its mechanism of action in a clinically vulnerable population and informing dose selection for late-phase clinical trials. This milestone will de-risk the program and position INNA-051 for global partnership and commercialisation.

If successful, ENA Respiratory’s INNA-051 could offer a simple, self-administered nasal spray used during high viral circulation to reduce illness, hospitalisation and disease progression in vulnerable populations and ease pressure on healthcare systems, as well as being deployed institutionally as part of outbreak preparedness.

  • BV Round 1 Project: Nasal Spray Treatment
  • State: NSW
  • Project Lead: Dr Christophe Demaison
  • Biointelect Venturer Funding: $2,983,000

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.